EXPLORER-LTE: An ongoing extension of the Phase 3 EXPLORER-HCM trial to evaluate the long-term efficacy and safety of CAMZYOS¹

EXPLORER-LTE study design*^†1

Adapted from Garcia-Pavia P et al. 2024.¹
*The data cutoff date for this interim analysis was 31 August 2023.^1
†Patients were assessed at 12-week intervals until Week 156, followed by assessments at 24-week intervals.^1
‡Dose adjustments were made based on evaluation of LVOT gradient with the Valsalva manoeuvre and LVEF using site-read echocardiogram readings (echocardiograms were also sent to the central laboratory for review).^1
§A site-read stress echocardiogram was also performed at Week 24 to evaluate the post-exercise LVOT gradient; a dose increase was allowed per the investigator’s request if the post-exercise LVOT gradient was ≥50 mmHg.²